Shom Goel

15PUBLICATIONS
133CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 12, 2026
Rb-driven transcription limits its tumour-suppressive effects in breast cancer.

|May 13, 2026
Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor-Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy.

|Feb 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer.

Ana C Garrido-Castro, Noah Graham, Lestat R Ali

|Feb 05, 2025
A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer.

Shom Goel, Bojana Jovanović, Xiangying Chu

|Aug 13, 2024
Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.

Bojana Jovanović, Sarah E Church, Kara M Gorman

|Jul 29, 2024
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.

Kamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler

Pageof 3

Frequent Collaborators

6 joint publications

Sara M Tolaney

3 joint publications

Lestat R Ali

3 joint publications

April C Watt

2 joint publications

Keefe T Chan